14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative

Details 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative

1995-12-26

1998-10-27

Robinson, Allen J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514171, 514182, 552510, 552601, 552602, 552604, 552605, 552606, 552607, 552608, A61K 3156

Patent

active

058278427

ABSTRACT:
The invention describes 14,17-C.sub.2 -bridged steroids of general formula (I), ##STR1## wherein the various R groups are as defined in the specification, and wherein said steroids are, in contrast with the disclaimed compound 14,17-ethano-19-norpregn-4-ene-3,20-dione bioavailable even after peroral administration with high gestagenic action and are suitable for the production of pharmaceutical agents.

REFERENCES:
A.J. Solo et al., Steroids: Structure, Function and Regulation, 18:251-259 (Sep. 1971).
A.J. Solo et al., Journal of Medicinal Chemistry, 16:270-273 (Mar. 1973).
J.R. Bull et al., South African Journal of Chemistry, 44:87-94 (Sep. 1991).
A.J. Solo et al., Journal of Pharmaceutical Sciences, 62:1471-1475 (Sep. 1973).

Affiliated with

Also associated with

Rating

14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1614014